We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $2.21B
1-Year Est. Return 431.26%
This Fund
S&P 500
This Quarter Est. Return
+12.85%
1 Year Est. Return
+431.26%
3 Year Est. Return
+1,487.3%
5 Year Est. Return
+3,318.95%
10 Year Est. Return
–
AUM
$286M
AUM Growth
-$16.7M
Cap. Flow
-$16.5M
Cap. Flow %
-5.78%
Top 10 Hldgs %
46.84%
Holding
97
New
24
Increased
16
Reduced
16
Closed
27

Top Buys

Rank Stock Value
1
KYNB
Kyntra Bio
KYNB
+$16.3M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$13M
3
BIIB icon
Biogen
BIIB
+$11.9M
4
ESTA icon
Establishment Labs
ESTA
+$6.8M
5
KURA icon
Kura Oncology
KURA
+$6.54M

Top Sells

Rank Stock Value
1
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$16.8M
2
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$16.1M
3
MRK icon
Merck
MRK
+$12.8M
4
VKTX icon
Viking Therapeutics
VKTX
+$6.75M
5
BLU
BELLUS Health Inc.
BLU
+$6.35M

Sector Composition

Rank Sector Weight
1 Healthcare 83.47%
2 Miscellaneous 16.53%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FHTX icon
76
Foghorn Therapeutics
FHTX
$292M
– –
-136,771
Closed -$848K
CBIO
77
PUT
Crescent Biopharma
CBIO
$776M
– –
-3,000
Closed -$378K
KPTI icon
78
Karyopharm Therapeutics
KPTI
$40.6M
– –
-30,732
Closed -$1.79M
LNTH icon
79
Lantheus
LNTH
$6.59B
– –
-30,244
Closed -$2.5M
MRK icon
80
Merck
MRK
$371B
– –
-120,000
Closed -$12.8M
MRNA icon
81
CALL
Moderna
MRNA
$58.1B
– –
-35,000
Closed -$5.38M
NVAX icon
82
PUT
Novavax
NVAX
$1.69B
– –
-346,800
Closed -$2.4M
ROIV icon
83
Roivant Sciences
ROIV
$25.2B
– –
-100,000
Closed -$738K
SCLX icon
84
Scilex Holding
SCLX
$38.1M
– –
-13
Closed -$3.8K
SCLXW icon
85
Scilex Holding Co Warrant
SCLXW
$1.53M
– –
-18,099
Closed -$19K
SPY icon
86
CALL
State Street SPDR S&P 500 ETF Trust
SPY
$815B
– –
-45,000
Closed -$18.4M
PVLA
87
Palvella Therapeutics
PVLA
$2.27B
– –
-3,837
Closed -$300K
NARI
88
DELISTED
Inari Medical, Inc. Common Stock
NARI
– –
-20,000
Closed -$1.23M
KRTX
89
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
– –
-12,500
Closed -$2.27M
PNT
90
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
– –
-149,586
Closed -$1.09M
SGEN
91
DELISTED
Seagen Inc. Common Stock
SGEN
– –
-20,000
Closed -$4.05M
BLU
92
DELISTED
BELLUS Health Inc.
BLU
– –
-881,329
Closed -$6.35M
RXDX
93
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
– –
-150,000
Closed -$16.1M
HZNP
94
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
– –
-20,000
Closed -$2.18M
1 2 3
4

Similar funds

BCP
BSN Capital Partners London, United Kingdom $2.21B AUM 22.85% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.21B AUM 28.12% 1-Year Est. Return
IHL
Investment House LLC Redondo Beach, California $2.21B AUM 39.6% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $2.21B AUM 28.75% 1-Year Est. Return
CCA
Checchi Capital Advisers Beverly Hills, California $2.22B AUM 23.18% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2.22B AUM 32.92% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
LI
Leeward Investments Boston, Massachusetts $2.2B AUM 46.08% 1-Year Est. Return

Affinity Asset Advisors's Q2 2023 Portfolio in Review

As of Q2 2023, Affinity Asset Advisors held 97 positions worth $286M, down 5.5% from $303M the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Affinity Asset Advisors withdrew a net $16.5M in Q2 2023, closing 27 positions and reducing 16 holdings. Its most notable exit was Prometheus Biosciences, Inc. Common Stock, an estimated $16.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, up from 79% a quarter earlier, followed by Miscellaneous.

Against the trend, Affinity Asset Advisors opened a new position in Kyntra Bio worth $2.65M.

  • Affinity Asset Advisors's largest Q2 2023 buy was Kyntra Bio: 39,332 shares worth $2.65M.
  • Affinity Asset Advisors added most to Establishment Labs in Q2 2023, an estimated $6.8M increase.
  • Affinity Asset Advisors's biggest Q2 2023 reduction was Chinook Therapeutics, Inc. Common Stock, cutting an estimated $16.8M.
  • Affinity Asset Advisors fully exited Prometheus Biosciences, Inc. Common Stock in Q2 2023, selling an estimated $16.1M.
  • Affinity Asset Advisors's ten largest holdings make up 47% of its $286M portfolio in Q2 2023.
  • Affinity Asset Advisors opened 24 new positions and closed 27 in Q2 2023.
  • Affinity Asset Advisors's portfolio value fell 5.5% quarter-over-quarter to $286M.

Based on Affinity Asset Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.